Navigation Links
Lengthening dosing schedule of HPV vaccine may provide effective option for expanding use of vaccine

Administration of human papillomavirus (HPV) vaccine doses over a longer period of time to adolescent girls in Vietnam resulted in antibody concentration levels that were comparable to the standard vaccine schedule, according to a study in the April 13 issue of JAMA, a theme issue on infectious disease and immunology.

Kathleen M. Neuzil, M.D., M.P.H., of PATH, Seattle, presented the findings of the study at a JAMA media briefing at the National Press Club in Washington, D.C.

Cervical cancer is an important cause of illness and death among women throughout the world. "Each year, new cases of cervical cancer occur in approximately 529,000 women and 275,000 women die. An estimated 88 percent of deaths due to cervical cancer occur among women residing in developing countries," according to background information in the article. Human papillomaviruses are the primary cause of cervical cancer. "Combined with continued strengthening of simple evidence-based screening and treatment approaches, effective HPV vaccine programs could reduce cervical cancer rates in developing countries to the low levels currently observed in many developed countries. One challenge to broadly implementing HPV vaccination programs in developing countries will be delivering the currently recommended 3 doses of vaccine to adolescents within 6 months (dosing schedules at 0, 2, and 6 months or at 0, 1, and 6 months)," the authors write. Even in settings in which such vaccination schedules are feasible, alternative schedules may have advantages, such as lower cost (the vaccine could be delivered with other health interventions) or increased coverage (it may be easier for girls and their families or for vaccinators).

Dr. Neuzil and colleagues conducted a randomized noninferiority trial (predetermined measured outcome of intervention not worse than that of standard dosing schedule) in northwestern Vietnam to determine the immunogenicity (the ability of the vaccine to stimulate an immune response) and reactogenicity (the capacity of a vaccine to produce adverse reactions) of alternative schedules of quadrivalent HPV vaccine. The study, conducted between October 2007 and January 2010, assessed 4 schedules of an HPV vaccine delivered in 21 schools to 903 adolescent girls (ages 11-13 years at enrollment). Intramuscular injection of 3 doses of quadrivalent HPV vaccine was delivered on a standard dosing schedule (at 0, 2, and 6 months) or one of 3 alternative dosing schedules (at 0, 3, and 9 months; at 0, 6, and 12 months; or at 0,12, and 24 months). Of the 903 girls, 809 (89.6 percent) received all 3 doses of vaccine and had a serum sample available for testing after the final dose of the HPV vaccine.

For all 4 vaccination schedule groups and vaccine types, the HPV geometric mean titers (GMTs; a measure of antibody concentrations) were low at the beginning of the study and increased significantly after receipt of 3 doses of the vaccine. For the intention-to-treat population and compared with the standard schedule group at 0, 2, and 6 months, the alternative schedule groups at 0, 3, and 9 months and 0, 6, and 12 months met noninferiority criteria (as gauged by level of antibody concentrations) for the anti-HPV-16 and anti-HPV-18 (HPV types) responses at 1 month after receipt of the third dose. Compared with the standard schedule group, the alternative schedule group at 0, 12, and 24 months met noninferiority criteria for HPV-18 but not for HPV-16.

The vaccine was generally well tolerated in each dosing schedule group. Pain at the injection site was the most common adverse event. No serious adverse events were found.

"The similarity of the immunogenicity and reactogenicity profiles of the HPV vaccine reported from this predominantly ethnic minority population in a low-resource area of Vietnam and other populations throughout the world is reassuring and supports more widespread introduction of the vaccine. The World Health Organization acknowledges that programmatic constraints must be considered in the decision to commence national HPV immunization programs. The option of delivering HPV vaccine on flexible schedules will allow countries to minimize costs and maximize feasibility according to local vaccination practices," the authors write.


Contact: Amy MacIver
JAMA and Archives Journals

Related medicine news :

1. SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
2. Cough Syrup Might Help With Dosing of Breast Cancer Drug
3. Confusion Over Drug Dosing Common for Seniors
4. The Ensign Group Schedules Year-End 2009 Earnings Call for Thursday, February 18, 2010
5. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
6. Enhances Dental Plan Benefits With New Fee Schedule
7. Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule
8. NIH/NHLBI-Funded PACT Program Announces Webcast Scheduled for Tuesday, May 4, 2010, 2:00-4:00 pm ET
9. Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs
10. The best and worst work schedules: Shift start times can impact sleep and alertness
11. Gold Standard/Elsevier first to launch state, federal controlled substance drug schedules
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... radiographic technicians must mark the film for accurate interpretation by the radiologist. The ... Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate this ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... (BHCOE) today announced that the organization has awarded Education and Developmental Therapies (EDT), ... Distinguished Award. The award celebrates exceptional special needs providers that excel in synthesizing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Lutronic, a leading ... Clarity, the latest addition to the devices for sale in the United States. ... Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 ... semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic ... Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Nurotron Biotechnology Co., ... its largest order to date. , The order will be from the China ... Venus Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex Health, ... GeneSight® Psychotropic test giving healthcare providers an expanded range ... for patients suffering from depression, anxiety, bipolar disorder, ... health conditions. i .   ... With the addition of two new drug ...
(Date:12/1/2015)... Calif. , Dec. 1, 2015 ... products and services, announced today that it has been ... services organization. Members served by Novation will have access ... devices, sports bracing products and soft goods dedicated to ... --> The aging U.S. population, rising prevalence ...
Breaking Medicine Technology: